361 were on GLP-1, and 618 were on non-GLP-1 RA medications
A typical taper from 12mg might step down to 8mg for two weeks, then 4mg for two weeks, then 2mg for two weeks before stopping entirely
[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits
10.1089/152091501750220037 60 WhithamM.FebbraioM
In the UK, Wegovy tablets are licensed for weight management, while orforglipron is still being studied in clinical trials and is not currently licensed
However, we also recognize that the most successful weight loss outcomes come from comprehensive weight loss programs that address the factors standard prescribers often miss